Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience.
Vincent L ChenM-L YehA K LeM JunW K SaeedJ D YangChung-Feng HuangH Y LeeP-C TsaiM-H LeeN GiamaN G KimP P NguyenH DangH A AliN ZhangJ-F HuangC-Y DaiW-L ChuangL R RobertsDae Won JunY-S LimMing-Lung YuMindie H NguyenPublished in: Alimentary pharmacology & therapeutics (2018)
Anti-viral therapy improved overall survival in patients with HBV-related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti-viral therapy in HBV-related HCC and better linkage-to-care for HBV patients are needed.
Keyphrases
- hepatitis b virus
- liver failure
- sars cov
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- palliative care
- gene expression
- dna methylation
- stem cells
- quality improvement
- hiv infected
- cell therapy
- pain management
- chronic pain
- drug induced
- patient reported outcomes
- combination therapy